Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding revenue by segment, R&D spend on new reverse shoulder systems, or FDA updates inside Enovis’s dense disclosures can feel like surgery without anesthesia. Each 10-K and 10-Q packs clinical data, regulatory risk, and intricate accounting across Prevention & Recovery and Reconstructive divisions. If you have ever typed “Enovis insider trading Form 4 transactions” or “How do I read an Enovis annual report 10-K simplified?” you already know the challenge.
Stock Titan removes the guesswork. Our AI reads every line the moment it hits EDGAR, then serves plain-English answers to real investor questions such as “Enovis quarterly earnings report 10-Q filing highlights” or “What changed in the latest Enovis 8-K material events explained?” You’ll see key metrics, red-flag language, and peer comparisons in seconds—not hours.
- Real-time alerts for Enovis Form 4 insider transactions — real-time so you never miss executive stock moves.
- Concise AI notes that make understanding Enovis SEC documents with AI straightforward.
- Side-by-side trend charts for every Enovis earnings report filing analysis across multiple quarters.
- Deep dives into the Enovis proxy statement executive compensation structure and how incentives align with surgical outcomes.
- Instant summaries of material FDA clearances from any 8-K.
Whether you’re screening “Enovis executive stock transactions Form 4” before the market opens or need an at-a-glance view of cash-flow shifts in the latest “Enovis quarterly earnings report 10-Q filing,” Stock Titan’s AI-powered analysis turns hundreds of technical pages into actionable knowledge. Explore every filing type, stay updated in real time, and make informed decisions faster.
Enovis (ENOV) reported Q3 2025 results with net sales of $548.9 million, up from $505.2 million a year ago, but recorded a non-cash goodwill impairment of $548.4 million. The charge drove an operating loss of $558.5 million and a net loss of $570.9 million, or $9.99 per share from continuing operations.
Both segments grew: Prevention & Recovery sales were $290.9 million and Reconstructive sales were $258.0 million. Adjusted EBITDA was $94.8 million versus $90.2 million, reflecting underlying operating performance despite elevated non-cash items.
The company approved and closed the sale of its Dr Comfort Footcare Solutions line to Promus Equity Partners for up to $60 million in cash, including $45 million upfront and up to $15 million contingent on milestones. Enovis recognized a $7.6 million loss on assets held for sale in connection with the transaction. Year-to-date, cash from operations was $128.7 million. Total debt was $1.36 billion, with $355 million available on the Revolver and a 5.75% weighted-average borrowing rate. Shares outstanding were 57.19 million as of October 31, 2025.
Enovis Corporation filed an 8-K announcing it issued a press release with financial results for the third quarter ended October 3, 2025.
The company scheduled a conference call for 8:30 a.m. Eastern on November 6, 2025 to discuss these results. The press release is included as Exhibit 99.1.
Enovis director Angela S. Lalor reported acquiring 742 shares of Enovis Corp (ENOV) on 09/30/2025 at a reported price of $0.00, increasing her direct beneficial ownership to 21,295 shares. The Form 4 shows the filing was signed by attorney-in-fact Brian P. Hanigan on 10/01/2025. The filing identifies Lalor as a director and indicates this is a single-person Form 4 filing. No derivative transactions or additional details are reported.
Damien McDonald, listed as Chief Executive Officer and Director of Enovis Corporation (ENOV), purchased 6,457 shares of Enovis common stock on 09/11/2025. The reported weighted-average price per share was $30.97, with transaction prices ranging from $30.73 to $31.16. After the purchase, the reporting person beneficially owned 102,753 shares. The Form 4 was signed on behalf of Mr. McDonald by attorney-in-fact Brian P. Hanigan.
Insider purchase by Enovis executive: Tandy Bradley J, SVP and Chief Legal Officer of Enovis Corporation (ENOV), reported purchasing 3,200 shares of Enovis common stock on 08/22/2025 at a price of $31.41 per share. After the transaction, Mr. Bradley beneficially owned 43,515 shares. The Form 4 was signed via attorney-in-fact on 08/25/2025.
Enovis insider purchase disclosed on Form 4. Philip Benjamin Berry, SVP and Chief Financial Officer, purchased 2,500 shares of Enovis Corporation (ticker ENOV) on 08/20/2025 at a price of $29.71 per share. After the transaction, Mr. Berry beneficially owned 116,729 shares. The Form 4 was filed as a single reporting person filing and was signed by attorney-in-fact Brian P. Hanigan on 08/20/2025.
The filing discloses that multiple American Century entities and the Stowers Institute report material beneficial ownership in Enovis Corporation common stock. American Century Investment Management, Inc., American Century Companies, Inc. and Stowers Institute each report beneficial ownership of 4,737,327 shares, representing 8.3% of the class, with sole voting power of 4,580,116 shares and sole dispositive power of 4,737,327 shares as shown on their cover pages. American Century Capital Portfolios, Inc. reports ownership of 3,060,000 shares, representing 5.4% of the class, with sole voting and dispositive power.
The filing states these securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. An exhibit shows that the reporting persons consented to a joint filing, and signatures certify the accuracy of the statement.
Davenport & Co LLC reported beneficial ownership of 2,756,270 shares of Enovis common stock, representing 4.83% of the class. The filer discloses sole voting power over 2,730,225 shares and sole dispositive power over 2,756,145 shares. The statement is filed on Schedule 13G as an investment adviser and indicates the holding is 5% or less of the class.
This filing also contains a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Enovis Corp. (ENOV) – Form 4 filing dated 08/07/2025
Group President, Recon, Louis Vogt reported one transaction on 08/05/2025. The Form 4 shows an F-code entry—shares withheld by the company to cover tax obligations arising from the net settlement of previously granted restricted stock units.
- Securities withheld: 460 common shares
- Price applied for withholding: $26.46 per share
- Post-transaction direct holdings: 36,385 common shares
Enovis Corporation (ENOV) filed a Form 4 disclosing an insider withholding transaction by reporting person John Kleckner, identified as the company's Principal Accounting Officer. On 08/05/2025, 173 shares of Enovis common stock were withheld in connection with the net settlement of restricted stock units to satisfy tax withholding obligations at a per‑share amount of $26.46. The filing explicitly notes this action does not represent a sale by the reporting person.
After the withholding, Mr. Kleckner beneficially owned 9,834 shares of Enovis common stock, held directly. The Form 4 was signed by attorney‑in‑fact Brian P. Hanigan on 08/07/2025. The filing includes the reporting person’s address in Wilmington, DE.
FAQ
What is the current stock price of Enovis (ENOV)?
What is the market cap of Enovis (ENOV)?
